Prognosis of Failure Treatment of Amebic Liver Abscess

This study has been completed.
Sponsor:
Collaborators:
Universidad Nacional Autonoma de Mexico
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Hospital Central "Dr. Ignacio Morones Prieto"
Information provided by:
Universidad Autonoma de San Luis Potosí
ClinicalTrials.gov Identifier:
NCT00641992
First received: March 12, 2008
Last updated: March 17, 2008
Last verified: March 2008
  Purpose

Amebic liver abscess is the most frequent extra-intestinal form of the amoebiasis; actually the factors for predicting failure in the medical treatment are not clear. We conducted trial for determining the clinical value of paraclinical factor in this issue.


Condition
Amebic Liver Abscess

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Prognosis Factors of the Response After Medical Treatment of Amebic Liver Abscess

Resource links provided by NLM:


Further study details as provided by Universidad Autonoma de San Luis Potosí:

Primary Outcome Measures:
  • Failure of medical treatment [ Time Frame: Day 4 ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: May 1999
Study Completion Date: April 2000
Primary Completion Date: April 2000 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Response to medical treatment
2
Failure to medical treatment (surgery or percutaneous resolution)

  Eligibility

Ages Eligible for Study:   16 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

sequential patients with clinical, ultrasonographic and serologic diagnosis (ELISA) of amebic liver abscess

Criteria

Inclusion Criteria:

  1. Clinical, ultrasonographic and serologic diagnosis (ELISA) of amebic liver abscess.
  2. Both genders
  3. Older 15 years

Exclusion Criteria:

  1. Clinically suspected piogenous liver abscess
  2. Positive hemoculture
  3. Negative ELISA for amoebic antigens
  4. Immunosupresion (HIV)
  5. Abdominal or biliary surgery antecedents
  6. Abdominal neoplasia antecedents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00641992

Locations
Mexico
Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán".
Mexico DF, Mexico
Faculty of Medicine, Universidad Autónoma de San Luis Potosí
San Luis Potosi, Mexico, 78210
Sponsors and Collaborators
Universidad Autonoma de San Luis Potosí
Universidad Nacional Autonoma de Mexico
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Hospital Central "Dr. Ignacio Morones Prieto"
Investigators
Principal Investigator: Martín Sánchez-Aguilar 1, MSc 1. Department of Experimental Surgery, Faculty of Medicine, Universidad Autónoma de San Luis Potosí
Study Director: Onofre Morán-Mendoza, PhD Department of Clinical Epidemiology, Faculty of Medicine, Universidad Autónoma de San Luis Potosí
  More Information

No publications provided

Responsible Party: Dr. Martin Sanchez Aguilar, Epidemiologia Clinica, Universidad Autonoma de San Luis Potosí
ClinicalTrials.gov Identifier: NCT00641992     History of Changes
Other Study ID Numbers: PFP-ALA
Study First Received: March 12, 2008
Last Updated: March 17, 2008
Health Authority: Mexico: National Institute of Public Health, Health Secretariat

Keywords provided by Universidad Autonoma de San Luis Potosí:
amebic liver abscess
failure
prognosis

Additional relevant MeSH terms:
Amebiasis
Abscess
Liver Abscess
Liver Abscess, Amebic
Suppuration
Infection
Inflammation
Pathologic Processes
Abdominal Abscess
Liver Diseases
Digestive System Diseases
Liver Diseases, Parasitic
Parasitic Diseases
Protozoan Infections

ClinicalTrials.gov processed this record on August 28, 2014